API Overage Calculation
How to size, justify and dispense API overage — the deliberate excess of active added at formulation so the finished product still meets label claim at end-of-shelf-life after every manufacturing loss and every degradation pathway.
Read the full summary
Worked in numbers, defensible in an inspection, and never used to mask process problems.
On this page · 7 sections
How does API Overage Calculation apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01The scenario
500 mg amoxicillin tablet, 60-tablet bottle. PPQ shows average manufacturing loss of 1.8% (blend transfer + compression waste, quantified). Long-term stability at 25 °C / 60% RH shows amoxicillin loss of 4.2% at 24 months per Arrhenius fit. Marketing authorisation approves 24-month shelf life at 30 °C / 65% RH.
02Overage is two numbers, not one
- Manufacturing overage — sized to the validated PPQ loss profile. Typical: 0.5–2.5% solid dose, 1–5% liquids, up to 8% sterile fill.
- Stability overage — sized to the certified stability curve at labelled storage conditions to shelf life. Typical: 0–3% stable solids, 2–8% liquids, exceeding 10% requires explicit Module 3 justification.
03Sizing the numbers from data
Manufacturing overage
From PPQ (three commercial-scale conformance batches) the mean loss is 1.8% with 3σ upper of 2.4%. Size to μ + 1σ (a common convention): 1.8% + 0.6% = 2.4%. Round to 2.5% for the recipe.
Stability overage
Arrhenius model fitted to 25 °C / 40 °C / 50 °C data. Loss at 30 °C over 24 months = 4.8% (upper 95% CI). Round to 5%.
Combined
2.5% + 5% = 7.5%. Above the EMA 5% threshold — requires Module 3 justification, but each component is independently justified from data. This is defensible.
04The dispense math
Label claim per tablet: 500 mg amoxicillin. Batch size: 100,000 tablets. Nominal batch active mass: 50.000 kg (anhydrous, free base).
| Step | Factor | Cumulative mass |
|---|---|---|
| Label claim (nominal) | — | 50.000 kg |
| + Stability overage (5%) | × 1.050 | 52.500 kg |
| + Manufacturing overage (2.5%) | × 1.025 | 53.813 kg |
| + Salt-to-base (trihydrate, SBF 1.129) | × 1.129 | 60.755 kg |
| + Moisture correction (LOD 0.6%) | × 1.006 | 61.120 kg |
| + Potency correction (assay 98.9%) | × 1.0111 | 61.798 kg |
| Adjusted charge (as-is) | — | 61.798 kg of amoxicillin trihydrate |
05Yield reconciliation at batch close
At batch end the actual loss is measured against the validated PPQ loss. If actual loss ≤ 2.5% (the manufacturing overage), the finished tablets meet label claim from t=0 forward per the stability model. If actual loss > 2.5%, the delta was not budgeted for and a deviation opens automatically.
06Special cases
- Highly potent APIs (HPAPI, OEB 4/5) — overage may be capped by toxicological limits before manufacturing/stability data caps it. Justification must include the safety margin calculation.
- Vitamin premixes — 21 CFR 111.70(e) and USP <2091> allow 5–15% for vitamin degradation; watch double-counting when the premix supplier already added overage.
- Combination products — each active gets its own overage stack; combined overage is not a single figure.
- Biologics — activity-loss overage on IU basis; stability model may be non-Arrhenius (protein aggregation), so overage sizing needs the correct kinetic model.
- Radiopharmaceuticals — decay overage is the dominant term; overage sizing is a decay calc, not a stability curve.
07How V5 Ultimate handles overage
Frequently asked questions
Q.Can we use a single 'overage' number instead of splitting manufacturing and stability?+
No. Regulators expect the components separately, each justified from its own data source. A single number hides which part is drifting and prevents targeted investigation.
Q.How often should overage be revisited?+
At every annual product review, at any process change (change control), and whenever PPQ or ongoing stability data shifts meaningfully. Overage is not set-and-forget.
Q.What if actual loss is consistently below the manufacturing overage?+
That's a chance to tighten it — capital-tied-up on excess API and a smaller safety margin against unexpected losses. Route through change control.
Q.Does overage apply to excipients?+
Only if the excipient has a critical role in bioavailability or stability. Most excipients are not overaged; they're QS'd via the counter-balance.
Primary sources
Further reading
Want to see how API Overage Calculation could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.